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Edited by Barry HalliwellAbstract Mallory bodies (MBs) are characteristic of several li-
ver disorders, and consist primarily of keratins with transgluta-
minase-generated keratin crosslinks. We tested the eﬀect of the
transglutaminase-2 (TG2) inhibitor KCC009 on MB formation
in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine
(DDC). KCC009 decreased DDC-induced liver enlargement
without aﬀecting MB formation or extent of liver injury. TG2
protein and activity increased after DDC feeding and localized
within and outside hepatocytes. KCC009 inhibited DDC-induced
hepatomegaly by aﬀecting hepatocyte cell size rather than prolif-
eration. Hence, TG2 is a potential mediator of injury-induced
hepatomegaly via modulation of hepatocyte hypertrophy, and
KCC009-mediated TG2 inhibition does not aﬀect mouse MB
formation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transglutaminases (TGs) are a family of enzymes which cat-
alyze a reaction between c-carboxamide groups of glutamines
and e-amino groups of lysines, thereby forming e-(c-glutamyl)
lysine intra- or inter-molecular crosslinks [1,2]. TG-generated
crosslinks can be beneﬁcial as occurs during blood clotting
or formation of the epidermal cell-envelope, but can be path-
ologic since they may lead to autoimmune disorders such as ce-
liac disease [3]. Within the TG family, TG2 (also known as
tissue transglutaminase) is ubiquitously expressed and impli-Abbreviations: Ab, antibody; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; ALP, alkaline phosphatase; DDC, 3,5-
diethoxycarbonyl-1,4-dihydrocollidine; ECM, extracellular matrix;
H&E, hematoxylin and eosin; IF, intermediate ﬁlament; Inh, trans-
glutaminase inhibitor; ip, intraperitoneal; K, keratin; KCC009, dihyd-
roisoxazole-derived transglutaminase inhibitor; MB, Mallory body;
MDC, monodansylcadaverine; PCNA, proliferating cell nuclear
antigen; Re, recovery; TG, transglutaminase; WGA, wheat germ
agglutinin
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doi:10.1016/j.febslet.2006.03.051cated in apoptosis, organization of extracellular matrix
(ECM) and signal transduction [1,2]. Many proteins are
known TG2 substrates, including intermediate ﬁlament (IF)
proteins [4,5]. The signiﬁcance of IF proteins as substrates
for TG2 is that IFs are the major components of a variety of
cytoplasmic inclusions that are associated with a range of dis-
eases that reﬂect the tissue-speciﬁc expression of IF proteins
[6]. Among the inclusions are Mallory bodies (MBs) that are
found in a variety of liver disorders [7], desmin bodies in mus-
cle [8], and neuroﬁlament and a-internexin inclusions in brain
[9]. IFs make up a large family of tissue-speciﬁc nuclear and
cytoplasmic proteins. Types I–IV cytoplasmic IFs include ker-
atins (K) type I (K9–K20) and II (K1–K8) of epithelial cells,
several type III proteins (e.g., desmin), and several type IV
proteins (e.g., neuroﬁlaments and a-internexin) [10]. Epithelial
cells may express four or more keratins but adult hepatocytes
are unique among glandular epithelia in that they express K8/
K18 exclusively [11]. K8/K18 are the major constituents of
MBs [7,11,12] and animal model studies showed that K8 is
essential for MB formation [13,14].
Targeting of TG2 as a potential modulator of inclusion dis-
eases is clinically attractive for several reasons. Transglutamin-
ase crosslinks have been found in animal models of MB [15]
and in patients with Parkinson [16] and Alzheimer [17] dis-
eases. In addition, transglutaminase inhibition improves the
phenotype and prolongs the lifespan of the Huntington mice
[18] and mating of these mice with transglutaminase knockouts
has a similar eﬀect [19]. A recently described group of TG2
inhibitors [20] oﬀer potential advantages over other existing
inhibitors such as monodansylcadaverine (MDC) and cysta-
mine due to their irreversible nature, tolerability (so far tested
only in rodents), speciﬁcity and short half-life [20]. Based on
these ﬁndings, we tested the hypothesis that pharmacologic
inhibition of TG2 may block MB formation, using the recently
described irreversible TG2-inhibitor halo-dihydroisoxazole-
derivative transglutaminase inhibitor (KCC009) (also termed
compound-1b [20]).2. Materials and methods
2.1. Animal experiments and TG2 activity
C3H mice were obtained from Taconic Farms (Germantown, NY)
and permitted ad libitum consumption of water and diet. The animal
experiments protocol was approved by the institutional Animal Care
Committee. For the inhibitor experiments, 2–3-months-old, age- and
sex-matched mice were injected intraperitoneally (ip) with KCC009blished by Elsevier B.V. All rights reserved.
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DMSO in PBS (v/v); or 200 mg/kg MDC (Fluka) (in DMSO). Similar
cystamine/MDC concentrations were previously used in rodents
[21,22], while KCC009 (chemically synthesized [20]) concentration is
based on its upper-range solubility in 60% DMSO.
MBs were induced by feeding a powdered Formulab Diet 5008
(Deans Animal Feeds) containing 0.1% 3,5-diethoxycarbonyl-1,4-dihy-
drocollidine (DDC) (Aldrich) for 3–3.5 months. Mice were recovered
for 4 weeks on a standard diet (termed ‘‘primed mice’’ after recovery,
Fig. 1A) then divided into three groups (8 mice/group). One group was
given KCC009 alone (20 mg/kg, 3·/d), and the remaining two groups
were re-fed the DDC-containing diet (6 d) either alone or with
KCC009 (20 mg/kg, 3·/d; ﬁrst KCC009 dose given 2 h before begin-
ning DDC feeding) in order to induce re-appearance of MBs. Mice
were sacriﬁced by CO2 inhalation 1–2 h after the last injection, and
blood was collected by intracardiac puncture for serologic testing.
Mouse livers were snap frozen in liquid nitrogen and stored
(80 C). Thawed tissues were dounced and sonicated in 50 mM man-
nitol, 2 mM Tris–HCl (pH 7.2). TG activity is based on [1,4-14C]-
putrescine (Amersham) incorporation into N,N-dimethyl casein (Sig-
ma) [23,24].Fig. 1. Impact of TG2 inhibition on re-appearance of MBs, animal weights
algorithm. Inh, the inhibitor KCC009. (B) Hematoxylin and eosin (H&E) (a
mice treated for 6 d with KCC009 (Inh) (a,d), DDC alone (b,e), or DDC + I
and DDC + Inh groups, whereas no MBs were apparent in livers of mice trea
(C) Serum transaminases (ALT, AST), alkaline phosphatase (ALP), bilirubin
and corrected percent weight loss (by subtracting the ﬁnal liver weight from t
in serum tests between the primed groups that received DDC or DDC + Inh,
Serum tests from control mice (two untreated and two vehicle-treated mice) a
Values are shown as means ± S.D. n.a. = not applicable. When comparing th
highlighted by ‘‘**’’, P = 0.07.2.2. Histological and immunoﬂuorescence staining, and in situ TG2
activity
Tissues were ﬁxed then stained with hematoxylin and eosin. For
immunoﬂuorescence staining, freshly-frozen liver pieces were ﬁxed
with 3% paraformaldehyde (actin staining) or acetone (all other stain-
ings). Immunoﬂuorescence and in situ TG2-activity staining were per-
formed as described [25,26] using the antibodies (Ab): Troma I (anti-
K8; [26]), anti-TG2 antibodies CUB7402 and TG100 (Labvision),
and anti-ﬁbronectin (Sigma). Cell borders were visualized using Texas
red-conjugated wheat germ agglutinin (WGA) and Alexa 488-coupled
phalloidin (Molecular Probes). Pictures were obtained using a TE300
microscope, a BioRad confocal and Lasersharp software (Zeiss). For
cell size measurement, ﬁve random high-power-ﬁeld images/sample
were acquired and cell borders were manually selected and the area
determined using Volocity software (Improvision).
2.3. Quantiﬁcation of keratin-containing MBs and immunoblotting
The percent cells with keratin-containing aggregates was estimated
using mouse liver sections stained with Troma I Ab. The relative
MB content was scored from 0 to 4 which corresponded to 0%, 1–
25%, 26–50%, 51–75% and 76–100% of cells with keratin-containingand serology. (A) Schematic of MB induction, priming and treatment
–c) and K8 immunoﬂuorescence (d–f) staining of livers isolated from
nh (c,f). Arrows point to MBs which were similarly noted in the DDC
ted with KCC009 alone. Bar = 50 lm (bar in ‘‘c’’, a–c; bar in ‘‘f’’, d–f).
, percent weight loss ([ﬁnal weight  initial weight/initial weight] · 100)
he ﬁnal animal weight) are shown. There were no signiﬁcant diﬀerences
while DDC re-challenge led to a signiﬁcant increase in all serum tests.
re shown in the upper row, 8 mice were used for the remaining groups.
e two groups highlighted by ‘‘*’’, P = 0.02; when comparing the groups
P. Strnad et al. / FEBS Letters 580 (2006) 2351–2357 2353aggregates (all sizes), respectively. At least 10 ﬁelds (20·) were evalu-
ated/section and eight diﬀerent livers were scored/group. Immunoblot-
ting was done using total liver homogenates (in 2% SDS) and primary
Abs [mouse anti-PCNA and anti-tubulin, rabbit anti-TG2 (all Labvi-
sion); mouse anti-caspase 9 (Immunotech)] as described [26].3. Results
3.1. KCC009 is well tolerated in a mouse MB reformation
model, but does not aﬀect MB generation
In preliminary experiments, we compared the eﬃcacy of
three TG2 inhibitors: cystamine, MDC and KCC009. All three
led to 25% inhibition of liver TG2 activity (not shown) but
MDC and cystamine appeared toxic leading to decreased ani-
mal movement and heavy breathing. In contrast, KCC009-in-
jected animals behaved similar to non-injected controls (not
shown), which led us to focus on KCC009. Presence of free
KCC009 was observed in liver tissue 1 h after drug administra-
tion, as conﬁrmed by mass spectrometry (not shown). The dos-
ing frequency of KCC009 was optimized by testing TG2
activity in mouse liver at diﬀerent intervals after a single ip
injection. The inhibitory activity of KCC009 remains up to
3 h but rebounds by 8 h (not shown). Hence, we used a 3·/d
ip dosing in the experiments described below.
In order to test the potential role of TG2 in MB formation,
we used the well-established rapid mouse MB reformation
model (Fig. 1A), whereby MB are initially induced by DDC
feeding, after which mice recover and most if not all MBs re-
solve after regular diet feeding for one month (which generates
‘‘primed mice’’) followed by re-feeding with DDC for <7 d
which induces a robust MB formation [27,28]. The eﬀect of
KCC009 on MB re-formation (rather than formation) was
tested during DDC re-feeding (instead of initial feeding),
which allows a ﬁnite use of the drug and avoids what would
otherwise be prohibitively large-scale synthesis. We adminis-
tered KCC009 alone or in combination with DDC for 6 d
and compared the liver phenotype to livers from DDC re-fed
mice (Fig. 1A). KCC009 did not signiﬁcantly alter the toxicity
of the re-introduced DDC, as determined by histological andFig. 2. Upregulation of TG2 in the liver after DDC feeding. (A) TG2 activity
Mice were sacriﬁced 1–2 h after the last KCC009 dose. TG2 activity (y-axis) re
homogenates were obtained from the livers used in panel A and used for imm
Ab. Equal amounts of protein were loaded/lane, and each lane corresponds
degradation product seen in mice fed DDC for 3.5 months. The TG2 blot o
shown, but analyzed on a separate gel).serologic assessment (Fig. 1B and C). However, the
KCC009 + DDC led to a signiﬁcantly higher weight loss when
compared to administering either drug individually (Fig. 1C).
This diﬀerence is related at least in part to the smaller liver
enlargement seen in the DDC + Inh regimen (see below), since
the corrected weight loss (excluding liver weights) diﬀerence
becomes smaller (Fig. 1C). With regard to MBs, DDC re-feed-
ing with or without simultaneous administration of KCC009
for 6 d led to re-appearance of keratin-containing aggregates
(Fig. 1B; arrows in panels e and f), which were also apparent
in histological staining (Fig. 1B; arrows in panels b and c).
There was no signiﬁcant diﬀerence in MB formation upon
KCC009 administration (MB scores were 2.4 and 2.9 for mice
treated with DDC alone and DDC + KCC009, respectively).
3.2. TG2 activity and distribution in response to DDC
We measured liver TG2 activity and protein levels. DDC
treatment caused a 4-fold increase in TG2 activity, which re-
turned to near baseline after 4 weeks of recovery. DDC re-
feeding elevated the TG2 activity 2.5-fold but less so when
KCC009 was included (Fig. 2A). The TG2 activity level
changes paralleled changes at the protein level as determined
by immunoblotting using anti-TG2 Ab (Fig. 2B). Similar
changes in transglutaminase activity were previously described
when mice were fed the MB-inducing agent griseofulvin [29].
Next we examined whether upregulation of TG2 after DDC
re-challenge aﬀects its distribution. A similar TG2 staining pat-
tern was found in DDC + Inh versus Inh-alone livers although
TG2 staining was brighter after DDC exposure with a promi-
nent staining that co-localizes with the extracellular matrix
protein ﬁbronectin (Fig. 3). Staining of TG2 protein and its
activity showed signiﬁcant co-localization although some areas
stained with anti-TG2 antibody but did not show any activity
staining (Fig. 4A, a–c). A signiﬁcant portion of TG2 activity
did not co-localize with cytoplasmic K8 (Fig. 4A, d–f;
Fig. 4B) but co-localized with ﬁbronectin (Fig. 4B, arrows in
panel a) and had intense staining just outside the keratin stain-
ing (Fig. 4B, arrowheads in panel b). In addition to extracellu-
lar TG2 staining, there was also diﬀuse cytoplasmic stainingwas measured in livers (2 mice/measurement) of the indicated groups.
presents pmol incorporated putrescine/mg protein/min. (B) Total tissue
unoblotting with anti-caspase 9 (used as loading control) and anti-TG2
to a homogenate from an individual liver. Asterisk points to a TG2
f ‘‘Re + Inh’’ had a similar intensity to the ‘‘Re alone’’ intensity (not
Fig. 3. Immunoﬂuorescence staining shows co-localization of ﬁbronectin and TG2 in livers of re-challenged animals. Livers from the indicated
treatments were double-stained using antibodies to ﬁbronectin (a–c; initial ﬂuorochrome of the secondary antibody was green) and TG2 (d–f; initial
ﬂuorochrome was red). The merged (green + red) images are displayed in the bottom panels. Note the extensive co-localization of TG2 and
ﬁbronectin. Bar = 50 lm.
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(Fig. 4B). The TG2 distribution was largely identical when
visualized with two independent anti-TG2 antibodies (Figs. 3
and 4A) or with a TG2 in situ activity assay (Fig. 4A).
3.3. TG2 inhibition blocks DDC-induced hepatocyte hypertrophy
DDC treatment for 3.5 months led to more than a 3-fold
increase in liver size, which returned to near normal after
four weeks of recovery (Fig. 5A). DDC re-feeding of primed
mice for 6 d caused a 75% increase in liver size whereas
treatment with KCC009 had no signiﬁcant eﬀect (Fig. 5A).
Interestingly, simultaneous administration of KCC009 and
DDC for 6 d led to only a 57% increase in liver size, which
represents 24% inhibition of the DDC-induced liver enlarge-
ment (Fig. 5A). The KCC009 eﬀect was not related to cell
proliferation since proliferating cell nuclear antigen (PCNA)
levels were similar in the KCC009 +/ groups (Fig. 5B).
However, the eﬀect of KCC009 on DDC-induced hepato-
megaly is related to inhibition of hepatocyte hypertrophy
as determined by quantiﬁcation of hepatocyte cell size
(Fig. 5C and D). As such, the average diﬀerence in hepato-
cyte cell area of 67 lm2 (358–291 = 67 lm2) (Fig. 5D) repre-
sents a 19% inhibition in cell size enlargement, which is
consistent with the 24% observed inhibition in liver weight
increase (Fig. 1C).4. Discussion
The major conclusions of our study are: (i) modest inhibition
of TG2 in the liver by KCC009 has no eﬀect on MB formation,
but has a signiﬁcant eﬀect on DDC-induced hepatomegaly
which suggests a role for TG2 in hepatocyte hypertrophy,
and (ii) the eﬀect of KCC009 on hepatocyte hypertrophy likely
represents a primarily ‘‘extracellular response’’ based on triple
staining results of TG2, TG2 activity and intra/extra cellular
markers (K8 and ﬁbronectin, respectively). KCC009 acts as a
pseudosubstrate that irreversibly inhibits only the active en-
zyme pool [20]. In general, 70–80% of TG2 is intracellular
in a dormant state due to low Ca2+ and high GTP, whereas
extracellular TG2 is preferentially active [30]. Therefore, we
posit that the limited liver TG2 inhibition by KCC009 likely
corresponds to inhibition of the catalytically-active extracellu-
lar pool. Support for extracellular TG2 protein/activity are
demonstrated by co-localization of TG2, TG2 activity and
ﬁbronectin (Figs. 3 and 4). KCC009 did not have an added
toxic eﬀect when co-administered with DDC (Fig. 1C), but
higher doses may be mildly hepatotoxic when given alone for
14 d ([20] and not shown).
Inhibition of TG2 by KCC009 did not aﬀect MB reforma-
tion upon DDC re-challenge in our experimental system. This
raises the possibility that TG2 may be more relevant for MB
Fig. 4. Localization of TG2 staining and activity in relation to K8 and ﬁbronectin. (A) Livers from mice with the indicated treatments were stained
to show: TG2 protein and activity (red and green, respectively; a–c), TG2 activity and K8 protein (green and blue, respectively; d–f) and an overlay
(g–i). Bar = 50 lm. (B) High magniﬁcation images of livers from untreated control mice show extensive co-localization between TG2 and ﬁbronectin
immunostaining (arrows in panel a) and the presence of signiﬁcant TG2 activity (arrowheads in panel b) outside the K8 staining that locates on the
inner aspect of the cell perimeter keratin-enriched zone (b). Bar = 10 lm.
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play any role in MB formation. If so then TG2-mediated ker-
atin crosslinking seen in MBs [15] may not be important for
MB formation or may be more relevant for MB formation
rather than reformation. For example, the highly stable TG2
crosslinks induced after prolonged DDC feeding may persist
in recovered mice and induce a rapid TG2-independent MB
re-appearance. However, TG2 induction is similar upon initial
and re-challenge exposures to DDC (Fig. 2), which suggests
that TG2 is likely to respond similarly in both biologic con-
texts. Alternatively, TG2-mediated crosslinking may not be di-rectly involved in protein aggregate formation, or may be
important depending on the inclusion type or experimental set-
ting. Also, TG2 crosslinking eﬀects may be counterbalanced by
its role in apoptosis (e.g., promotion of cell death of inclusion-
containing cells), adhesion or cell signaling [1,2,30]. Further-
more, experiments using pharmacological and genetic ablation
of TG2 may vary due to confounding factors inherent to both
models. For example, neuronal inclusions became more prom-
inent when Huntington mice were mated with transglutamin-
ase knockouts [19]. However, cystamine treatment of
Huntington mice decreased the number and size of aggregates
Fig. 5. Eﬀect of KCC009 on DDC-induced liver enlargement. (A) The percent liver to body weight is shown for the indicated mouse groups. Each
category of re-challenged mice included livers from 8 mice, while livers from 4 mice were used in the remaining groups. (B) Equal amounts of liver
homogenates (from the mice in Panel A) were immunoblotted using antibodies to tubulin (loading control) and PCNA. (C) and (D) Liver sections
from the indicated groups were double-stained with phalloidin (F-actin) and wheat germ agglutinin (WGA; binds carbohydrate moieties of the cell
surface). The average cell size was determined in four randomly selected mice (1–4) from each group of 8 mice. The mean cell area (±S.D.) is shown
for each group. Bar = 50 lm.
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mine has additional non-TG2-related eﬀects such as caspase
inhibition [31]. In contrast, TG inhibitors, including KCC009
and MDC, have pro-apoptotic eﬀects that enhance chemosen-
sitivity of glioblastomas [32].
The eﬀect of KCC009 on hepatocyte hypertrophy and the
link between TG2 and hepatocyte size is a novel ﬁnding.
This in vivo link may be due to intracellular or/and extracel-
lular eﬀects. Relevant to these ﬁndings, TG2 mediates, pos-
sibly via extracellular eﬀects, chondrocyte hypertrophy; and
cardiac TG2 over-expression induces organ enlargement
[33,34]. A TG2 extracellular eﬀect on hepatocyte hypertro-
phy may be supported by the established role of TG2 in
crosslinking extracellular matrix proteins, which may provide
mechanical extracellular stabilizing eﬀects to promote cell
growth. In the experimental system herein, further support
is based on the lack of a KCC009 eﬀect on MB formation
(a predicted intracellular eﬀect). Taken together, our ﬁndings
suggest that TG2 is a mediator of hepatic hypertrophy
which meshes well with the up-regulation of TG2 in multiple
liver injury models and the associated observed liver enlarge-
ment.
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